Morgan Stanley analyst Jeffrey Hung maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report) today and set a price target of $73.00. The company’s shares closed last Monday at $43.00.
According to TipRanks.com, Hung is a 4-star analyst with an average return of 19.1% and a 63.3% success rate. Hung covers the Healthcare sector, focusing on stocks such as Voyager Therapeutics, Acceleron Pharma, and Neurocrine.
Ultragenyx Pharmaceutical has an analyst consensus of Strong Buy, with a price target consensus of $69.00.
Based on Ultragenyx Pharmaceutical’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $113 million. In comparison, last year the company had a GAAP net loss of $87.31 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita.